Alembic Pharma Reports Q4 2025 Results: 7% Revenue Rise, 18% EBITDA Margin
Discover Alembic Pharmaceuticals’ Q4 2025 unaudited results: 7 % revenue growth, 18 % EBITDA margin, and a 1.5 % share rise—key insights for investors.
- Alembic Pharmaceuticals Limited
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read